Myriad Genetics, Inc. MYGN
Set alert
At close
Pre-market · Nov 3, 4:00 AM ET
- YTD
- -4.88%
- 1 year
- -27.24%
- Open
- 6.36
- Prev close
- 6.35
- Mkt cap
- 559.55M
- Vol
- 1.35M
- Avg vol
- 2.42M
- EPS
- -1.18
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 5.82
- High
- 6.46
- Forward P/E
- 71.53
- Beta
- 1.89
- Short ratio
- 4.83
- Inst. own
- 103.89%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 13.32
- 200-d avg
- 21.11
- 1y target
- 19.41
News
12 hours ago globenewswire.com
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
SALT LAKE CITY, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces that Myriad management will…
1 week ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers SCWorx (NASDAQ:WORX) stock moved upwards by 42.9% to $3.83 during Tuesday's regular session. Myriad Genetics (NASDAQ:MYGN) shares moved upwards by 36.85% to $5.76. The company's market cap…
1 week ago benzinga.com
Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp
Labcorp will purchase Myriad Genetics' prenatal testing business for $210 million in cash, projecting $160 million in year-one revenue.
1 week ago benzinga.com
Nasdaq Rises Over 100 Points; 3M Earnings Top Views
U.S. stocks rose Tuesday, led by the Dow, as 3M beat estimates. Braze and Myriad surged, while GM fell; oil and silver gained.
1 week ago benzinga.com
Hasbro Posts Upbeat Q3 Earnings, Joins Myriad Genetics, Equifax And Other Big Stocks Moving Higher On Tuesday
U.S. stocks mixed; Dow rose 400 points. Hasbro surged on strong earnings and outlook, while Braze, Myriad Genetics and others gained.
-
1 week ago benzinga.com
Myriad Genetics To Sell Its Prenatal Health Testing Business, Including Prequel, Foresight, SneakPeek And FirstGene Tests, To Labcorp For $210M In Cash Plus Inventory Value
When complete, the transaction is expected to provide more patients and physicians with expanded access to Labcorp’s comprehensive, high-quality laboratory services, convenient patient service center…
-
2 weeks ago benzinga.com
TD Cowen Maintains Hold on Myriad Genetics, Raises Price Target to $4.5
TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and raises the price target from $4 to $4.5.
-
3 weeks ago benzinga.com
SOPHiA GENETICS, Myriad Genetics Collaborate To Advance New Prostate Cancer-specific Genomic Instability Score Technology
SOPHiA GENETICS (NASDAQ:SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support…